Exploring the Global Thrombophilia Market: A Comprehensive Overview

The thrombophilia market size has grown strongly in recent years. It will grow from $15.97 billion in 2023 to $17.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing awareness, research and development in anticoagulant therapies, aging population, genetic research, increased incidence of thrombotic disorders.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $23.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine, emergence of novel therapies, integration of artificial intelligence, healthcare policy and regulation, increased patient education and empowerment. Major trends in the forecast period include technological advancements , expanded role of telemedicine, rising incidence rates, biopharmaceutical developments, collaborative research initiatives.

Market Overview -
Thrombophilia is a blood disorder that increases the risk of blood clotting in the veins and arteries. It can be caused by blood clotting in arteries and veins or by an inherited (genetic) or acquired disposition. It has the potential to cause a heart attack, stroke, kidney failure, and pulmonary embolism.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9439&type=smp

Surge In Elderly Population Propels Growth In The Thrombophilia Market
An increase in the elderly population is expected to propel the growth of the thrombophilia market going forward. The elderly population refers to those aged 65 and up, with the proportion of the dependent population determined as the total elderly and youth population expressed as a ratio of the total population. Thrombophilic risk factors are common in elderly adults and allow for the identification of a population at risk for poor clinical outcomes, hence, the rise in the elderly population will boost the market as it creates demand for thrombophilia drugs. For instance, according to the data released by America's Health Rankings, a US-based organization that evaluates health outcomes, in 2022, more than 56 million adults aged 65 and older account for around 16.9% of the total US population. More than 73.1 million older people are expected by 2030, when the last of the baby boomer generation enters old age. Therefore, the increase in the elderly population is driving the growth of the thrombophilia market.

Competitive Landscape -
Major companies operating in the thrombophilia market report are Pfizer Inc., F. Hoffmann-La Roche Limited, Mylan N.V., Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Aspen Insurance Holdings Limited, Sanofi SA, Eisai Co. Limited, Boehringer Ingelheim GmbH, Siemens, LabCorp, Instrumentation Laboratory SpA, Johnson & Johnson, Laurus Lab, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, GlaxoSmithKline plc, CSL Behring .

Groundbreaking Technological Advances And Long-Acting Drugs On The Horizon
Technological advancements are the key trend gaining popularity in the thrombophilia market. Major companies operating in the market are developing innovative technologies to sustain their position in the market. For instance, in 2021, the University of Oslo, a Norway-based public research university, created a brand-new technology known as super albumin that may result in the creation of long-acting drugs and have important consequences for people who suffer from hemophilia, a condition that damages the blood's capacity to clot. The university's research group developed a cutting-edge biomedical technique that can be utilized to produce coagulation factors with a significantly longer half-life than those that are available at present. The starting point is a detailed investigation of a biological mechanism. They were able to produce super albumin, a protein variant that can be coupled with protein-based drugs to extend their bloodstream half-life, using the knowledge they gained from this research.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Key Segments -

The thrombophilia market covered in this report is segmented -
1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
2) By Drugs: Heparin, Warfarin, Other Drugs
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End-Users: Hospitals, Homecare, Speciality Centres, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.